Akero Therapeutics Future Growth

Future criteria checks 0/6

Akero Therapeutics is forecast to grow earnings and revenue by 6.4% and 72.4% per annum respectively. EPS is expected to grow by 11.6% per annum. Return on equity is forecast to be -186.1% in 3 years.

Key information

6.4%

Earnings growth rate

11.6%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	72.4%
Future return on equity	-186.1%
Analyst coverage	Good
Last updated	12 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqGS:AKRO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	36	-338	-309	-303	4
12/31/2025	N/A	-320	-291	-257	5
12/31/2024	N/A	-265	-189	-161	5
9/30/2024	N/A	-237	-213	-212	N/A
6/30/2024	N/A	-204	-192	-191	N/A
3/31/2024	N/A	-179	-156	-156	N/A
12/31/2023	N/A	-152	-145	-145	N/A
9/30/2023	N/A	-120	-122	-122	N/A
6/30/2023	N/A	-116	-97	-97	N/A
3/31/2023	N/A	-112	-94	-94	N/A
12/31/2022	N/A	-112	-93	-93	N/A
9/30/2022	N/A	-121	-94	-94	N/A
6/30/2022	N/A	-110	-84	-84	N/A
3/31/2022	N/A	-112	-84	-84	N/A
12/31/2021	N/A	-101	-80	-80	N/A
9/30/2021	N/A	-98	-76	-76	N/A
6/30/2021	N/A	-95	-75	-75	N/A
3/31/2021	N/A	-82	-78	-78	N/A
12/31/2020	N/A	-79	-71	-71	N/A
9/30/2020	N/A	-65	-59	-59	N/A
6/30/2020	N/A	-59	-59	-59	N/A
3/31/2020	N/A	-50	-41	-41	N/A
12/31/2019	N/A	-44	-36	-36	N/A
9/30/2019	N/A	-90	-26	-26	N/A
6/30/2019	N/A	-86	-15	-15	N/A
3/31/2019	N/A	-87	-15	-10	N/A
12/31/2018	N/A	-82	-10	-5	N/A
9/30/2018	N/A	-22	-9	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AKRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AKRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AKRO is forecast to have no revenue next year.

High Growth Revenue: AKRO is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AKRO is forecast to be unprofitable in 3 years.

Akero Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 13% to US$48.38

Price target decreased by 29% to US$48.44

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Price target increased to US$52.00

Price target increased to US$48.33

Recent updates

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024

Akero Therapeutics, Inc. Provides Business Update

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Akero Therapeutics: Good Candidate For The MASH Basket

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

New major risk - Revenue and earnings growth

Executive VP notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc

Co-Founder notifies of intention to sell stock

Akero Therapeutics' EFX Data Warrants Caution

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Price target increased by 13% to US$48.38

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

President exercised options and sold US$368k worth of stock

Co-Founder recently sold US$440k worth of stock

Price target decreased by 29% to US$48.44

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New major risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

President notifies of intention to sell stock

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

President exercised options and sold US$920k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold US$2.1m worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

President exercised options and sold US$1.2m worth of stock

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Co-Founder exercised options and sold US$544k worth of stock

Price target increased to US$52.00

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

President exercised options and sold US$455k worth of stock

Independent Director recently sold US$1.1m worth of stock

President exercised options and sold US$428k worth of stock

Independent Director recently sold US$12m worth of stock

Price target increased to US$48.33

Co-Founder & Chief Scientific Officer exercised options and sold US$299k worth of stock

Akero Therapeutics announces closing of upsized public offering

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero adds over 100% rallying peers after NASH success

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Price target decreased to US$41.67